Patent 11014923 was granted and assigned to Incyte on May, 2021 by the United States Patent and Trademark Office.
The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR4 enzyme and are useful in the treatment of FGFR4-associated diseases such as cancer.